Equities Analysts Issue Forecasts for C4 Therapeutics, Inc.’s Q3 2023 Earnings (NASDAQ:CCCC)

Posted by Defense World Staff on Aug 12th, 2023

C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Analysts at Leerink Partnrs boosted their Q3 2023 EPS estimates for C4 Therapeutics in a note issued to investors on Tuesday, August 8th. Leerink Partnrs analyst C. Liu now anticipates that the company will earn ($0.71) per share for the quarter, up from their prior estimate of ($0.76). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($2.80) per share. Leerink Partnrs also issued estimates for C4 Therapeutics’ Q4 2023 earnings at ($0.62) EPS, FY2023 earnings at ($2.76) EPS, FY2024 earnings at ($3.05) EPS, FY2025 earnings at ($3.28) EPS and FY2026 earnings at ($0.56) EPS.

CCCC has been the subject of several other reports. Evercore ISI lowered their price objective on shares of C4 Therapeutics to $10.00 in a report on Tuesday, May 30th. UBS Group decreased their target price on shares of C4 Therapeutics from $22.00 to $20.00 in a research note on Friday, July 21st. Finally, HC Wainwright decreased their target price on shares of C4 Therapeutics from $25.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.13.

View Our Latest Analysis on C4 Therapeutics

C4 Therapeutics Trading Down 0.6 %

C4 Therapeutics stock opened at $3.41 on Friday. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $4.02. The firm has a market cap of $167.74 million, a P/E ratio of -1.20 and a beta of 2.02. C4 Therapeutics has a 1-year low of $2.60 and a 1-year high of $12.61.

Institutional Investors Weigh In On C4 Therapeutics

A number of large investors have recently added to or reduced their stakes in CCCC. Swiss National Bank grew its position in C4 Therapeutics by 7.9% in the 1st quarter. Swiss National Bank now owns 28,800 shares of the company’s stock worth $699,000 after purchasing an additional 2,100 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of C4 Therapeutics by 141.7% during the 1st quarter. JPMorgan Chase & Co. now owns 69,420 shares of the company’s stock worth $1,684,000 after acquiring an additional 40,698 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of C4 Therapeutics by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 127,072 shares of the company’s stock worth $3,083,000 after acquiring an additional 1,601 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of C4 Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 21,112 shares of the company’s stock worth $512,000 after acquiring an additional 7,792 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of C4 Therapeutics by 6.3% during the 1st quarter. Rhumbline Advisers now owns 40,699 shares of the company’s stock worth $987,000 after acquiring an additional 2,423 shares during the last quarter. Institutional investors own 70.98% of the company’s stock.

C4 Therapeutics Company Profile

(Get Free Report)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.